# Ceribell, Inc.: financial statements, quarterly CBLL · Nasdaq · CIK 1861107 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cbll.md) · [Financials](/companies/cbll/financials.md) · [Filings](/companies/cbll/filings.md) · [Insiders](/companies/cbll/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cbll/financials.md?period=annual). ## Income statement | Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.6](/filings/0000950170-24-125409.md) | [13.1 d](/filings/0000950170-25-026773.md) | [14.4](/filings/0000950170-25-067097.md) | [15.3](/filings/0000950170-25-103142.md) | [17.2](/filings/0001193125-25-264882.md) | [18.5 d](/filings/0001193125-26-067238.md) | [20.5](/filings/0001193125-26-217008.md) | [21.2](/filings/0001193125-26-342574.md) | [22.6](/filings/0001193125-25-264882.md) | [24.8 d](/filings/0001193125-26-067238.md) | [26.5](/filings/0001193125-26-217008.md) | [28.1](/filings/0001193125-26-342574.md) | | Cost of revenue | $m | [1.9](/filings/0000950170-24-125409.md) | [2.0 d](/filings/0000950170-25-026773.md) | [2.1](/filings/0000950170-25-067097.md) | [2.2](/filings/0000950170-25-103142.md) | [2.2](/filings/0001193125-25-264882.md) | [2.3 d](/filings/0001193125-26-067238.md) | [2.5](/filings/0001193125-26-217008.md) | [2.5](/filings/0001193125-26-342574.md) | [2.6](/filings/0001193125-25-264882.md) | [3.1 d](/filings/0001193125-26-067238.md) | [3.4](/filings/0001193125-26-217008.md) | [2.2](/filings/0001193125-26-342574.md) | | Gross profit | $m | [9.7](/filings/0000950170-24-125409.md) | [11.1 d](/filings/0000950170-25-026773.md) | [12.3](/filings/0000950170-25-067097.md) | [13.2](/filings/0000950170-25-103142.md) | [15.0](/filings/0001193125-25-264882.md) | [16.2 d](/filings/0001193125-26-067238.md) | [18.0](/filings/0001193125-26-217008.md) | [18.7](/filings/0001193125-26-342574.md) | [19.9](/filings/0001193125-25-264882.md) | [21.6 d](/filings/0001193125-26-067238.md) | [23.1](/filings/0001193125-26-217008.md) | [25.9](/filings/0001193125-26-342574.md) | | Research and development | $m | [2.3](/filings/0000950170-24-125409.md) | [2.7 d](/filings/0000950170-25-026773.md) | [3.0](/filings/0000950170-25-067097.md) | [3.3](/filings/0000950170-25-103142.md) | [3.4](/filings/0001193125-25-264882.md) | [3.9 d](/filings/0001193125-26-067238.md) | [4.2](/filings/0001193125-26-217008.md) | [4.9](/filings/0001193125-26-342574.md) | [5.0](/filings/0001193125-25-264882.md) | [5.1 d](/filings/0001193125-26-067238.md) | [6.2](/filings/0001193125-26-217008.md) | [6.7](/filings/0001193125-26-342574.md) | | Operating income | $m | [(7.2)](/filings/0000950170-24-125409.md) | [(8.4) d](/filings/0000950170-25-026773.md) | [(8.5)](/filings/0000950170-25-067097.md) | [(8.4)](/filings/0000950170-25-103142.md) | [(9.9)](/filings/0001193125-25-264882.md) | [(12.9) d](/filings/0001193125-26-067238.md) | [(14.2)](/filings/0001193125-26-217008.md) | [(15.0)](/filings/0001193125-26-342574.md) | [(14.6)](/filings/0001193125-25-264882.md) | [(14.6) d](/filings/0001193125-26-067238.md) | [(20.7)](/filings/0001193125-26-217008.md) | [(20.0)](/filings/0001193125-26-342574.md) | | Interest expense | $m | [0.5](/filings/0000950170-24-125409.md) | [0.5 d](/filings/0000950170-25-026773.md) | [0.4](/filings/0000950170-25-067097.md) | [0.5](/filings/0000950170-25-103142.md) | [0.5](/filings/0001193125-25-264882.md) | [0.5 d](/filings/0001193125-26-067238.md) | [0.5](/filings/0001193125-26-217008.md) | [0.5](/filings/0001193125-26-342574.md) | [0.5](/filings/0001193125-25-264882.md) | [0.5 d](/filings/0001193125-26-067238.md) | [0.4](/filings/0001193125-26-217008.md) | [0.4](/filings/0001193125-26-342574.md) | | Income tax | $m | not reported | [0.0 d](/filings/0000950170-25-026773.md) | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-342574.md) | not reported | not reported | not reported | [0.0](/filings/0001193125-26-342574.md) | | Net income | $m | [(7.1)](/filings/0000950170-24-125409.md) | [(8.3) d](/filings/0000950170-25-026773.md) | [(8.5)](/filings/0001193125-25-264882.md) | [(8.9)](/filings/0001193125-25-264882.md) | [(10.4)](/filings/0001193125-25-264882.md) | [(12.6) d](/filings/0001193125-26-067238.md) | [(12.8)](/filings/0001193125-26-342574.md) | [(13.6)](/filings/0001193125-26-342574.md) | [(13.5)](/filings/0001193125-25-264882.md) | [(13.5) d](/filings/0001193125-26-067238.md) | [(19.7)](/filings/0001193125-26-342574.md) | [(19.3)](/filings/0001193125-26-342574.md) | | Diluted EPS | $ per share | [(1.32)](/filings/0000950170-24-125409.md) | not reported | [(1.56)](/filings/0000950170-25-067097.md) | [(1.61)](/filings/0000950170-25-103142.md) | [(1.85)](/filings/0001193125-25-264882.md) | not reported | [(0.36)](/filings/0001193125-26-217008.md) | [(0.38)](/filings/0001193125-26-342574.md) | [(0.37)](/filings/0001193125-25-264882.md) | not reported | [(0.52)](/filings/0001193125-26-217008.md) | [(0.51)](/filings/0001193125-26-342574.md) | | Basic EPS | $ per share | [(1.32)](/filings/0000950170-24-125409.md) | not reported | [(1.56)](/filings/0000950170-25-067097.md) | [(1.61)](/filings/0000950170-25-103142.md) | [(1.85)](/filings/0001193125-25-264882.md) | not reported | [(0.36)](/filings/0001193125-26-217008.md) | [(0.38)](/filings/0001193125-26-342574.md) | [(0.37)](/filings/0001193125-25-264882.md) | not reported | [(0.52)](/filings/0001193125-26-217008.md) | [(0.51)](/filings/0001193125-26-342574.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | not reported | [34.5](/filings/0000950170-25-026773.md) | not reported | not reported | [14.1](/filings/0000950170-24-125409.md) | [194](/filings/0001193125-26-067238.md) | [153](/filings/0000950170-25-067097.md) | [40.1](/filings/0000950170-25-103142.md) | [23.7](/filings/0001193125-25-264882.md) | [40.5](/filings/0001193125-26-342574.md) | [45.3](/filings/0001193125-26-217008.md) | [32.7](/filings/0001193125-26-342574.md) | | Current assets | $m | not reported | [52.0](/filings/0000950170-25-026773.md) | not reported | not reported | [35.0](/filings/0000950170-24-125409.md) | [217](/filings/0001193125-26-067238.md) | [205](/filings/0000950170-25-067097.md) | [200](/filings/0000950170-25-103142.md) | [192](/filings/0001193125-25-264882.md) | [187](/filings/0001193125-26-342574.md) | [169](/filings/0001193125-26-217008.md) | [158](/filings/0001193125-26-342574.md) | | Total assets | $m | not reported | [58.9](/filings/0000950170-25-026773.md) | not reported | not reported | [47.1](/filings/0000950170-24-125409.md) | [225](/filings/0001193125-26-067238.md) | [213](/filings/0000950170-25-067097.md) | [208](/filings/0000950170-25-103142.md) | [200](/filings/0001193125-25-264882.md) | [196](/filings/0001193125-26-342574.md) | [178](/filings/0001193125-26-217008.md) | [166](/filings/0001193125-26-342574.md) | | Current liabilities | $m | not reported | [21.6](/filings/0000950170-25-026773.md) | not reported | not reported | [13.1](/filings/0000950170-24-125409.md) | [13.0](/filings/0001193125-26-067238.md) | [11.8](/filings/0000950170-25-067097.md) | [15.0](/filings/0000950170-25-103142.md) | [15.2](/filings/0001193125-25-264882.md) | [19.2](/filings/0001193125-26-342574.md) | [16.2](/filings/0001193125-26-217008.md) | [17.2](/filings/0001193125-26-342574.md) | | Total liabilities | $m | not reported | [23.8](/filings/0000950170-25-026773.md) | not reported | not reported | [35.6](/filings/0000950170-24-125409.md) | [34.2](/filings/0001193125-26-067238.md) | [32.6](/filings/0000950170-25-067097.md) | [35.5](/filings/0000950170-25-103142.md) | [35.4](/filings/0001193125-25-264882.md) | [40.5](/filings/0001193125-26-342574.md) | [37.3](/filings/0001193125-26-217008.md) | [38.0](/filings/0001193125-26-342574.md) | | Shareholders' equity | $m | [(105)](/filings/0000950170-24-125409.md) | [(112)](/filings/0001193125-26-067238.md) | [(120)](/filings/0001193125-25-264882.md) | [(127)](/filings/0001193125-25-264882.md) | [(136)](/filings/0001193125-25-264882.md) | [191](/filings/0001193125-26-342574.md) | [181](/filings/0001193125-26-342574.md) | [172](/filings/0001193125-26-342574.md) | [164](/filings/0001193125-25-264882.md) | [155](/filings/0001193125-26-342574.md) | [141](/filings/0001193125-26-342574.md) | [128](/filings/0001193125-26-342574.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(6.7) d](/filings/0000950170-25-026773.md) | [(9.6)](/filings/0000950170-25-067097.md) | [(7.0) d](/filings/0000950170-25-103142.md) | [(8.5) d](/filings/0001193125-25-264882.md) | [(10.0) d](/filings/0001193125-26-067238.md) | [(11.4)](/filings/0001193125-26-217008.md) | [(7.5) d](/filings/0001193125-26-342574.md) | [(11.1) d](/filings/0001193125-25-264882.md) | [(10.8) d](/filings/0001193125-26-067238.md) | [(19.3)](/filings/0001193125-26-217008.md) | [(12.9) d](/filings/0001193125-26-342574.md) | | Capital expenditure | $m | [0.5 d](/filings/0000950170-25-026773.md) | [0.1](/filings/0000950170-25-067097.md) | [0.3 d](/filings/0000950170-25-103142.md) | [0.6 d](/filings/0001193125-25-264882.md) | [0.4 d](/filings/0001193125-26-067238.md) | [0.1](/filings/0001193125-26-217008.md) | [0.1 d](/filings/0001193125-26-342574.md) | [0.4 d](/filings/0001193125-25-264882.md) | [0.2 d](/filings/0001193125-26-067238.md) | [0.1](/filings/0001193125-26-217008.md) | [0.0 d](/filings/0001193125-26-342574.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | period not labelled (2023-09-30) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [5.3](/filings/0000950170-24-125409.md) | [5.5](/filings/0000950170-25-067097.md) | [5.6](/filings/0000950170-25-103142.md) | [5.6](/filings/0001193125-25-264882.md) | [35.9](/filings/0001193125-26-217008.md) | [36.3](/filings/0001193125-26-342574.md) | [36.8](/filings/0001193125-25-264882.md) | [37.7](/filings/0001193125-26-217008.md) | [38.0](/filings/0001193125-26-342574.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 38,378,101 at 2026-08-06, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342574.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.